HRP20100304T1 - Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze - Google Patents
Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze Download PDFInfo
- Publication number
- HRP20100304T1 HRP20100304T1 HR20100304T HRP20100304T HRP20100304T1 HR P20100304 T1 HRP20100304 T1 HR P20100304T1 HR 20100304 T HR20100304 T HR 20100304T HR P20100304 T HRP20100304 T HR P20100304T HR P20100304 T1 HRP20100304 T1 HR P20100304T1
- Authority
- HR
- Croatia
- Prior art keywords
- enantiomer
- group
- formula
- compound
- day
- Prior art date
Links
- 230000008579 epileptogenesis Effects 0.000 title claims abstract 6
- 150000004657 carbamic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 33
- 206010015037 epilepsy Diseases 0.000 claims abstract 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 7
- 229910052801 chlorine Inorganic materials 0.000 claims abstract 7
- 239000000460 chlorine Substances 0.000 claims abstract 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 7
- 239000001257 hydrogen Substances 0.000 claims abstract 7
- 150000002148 esters Chemical class 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims abstract 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract 4
- 229910052794 bromium Inorganic materials 0.000 claims abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 4
- 239000011737 fluorine Substances 0.000 claims abstract 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract 4
- 125000005843 halogen group Chemical group 0.000 claims abstract 4
- 150000002367 halogens Chemical group 0.000 claims abstract 4
- 229910052740 iodine Inorganic materials 0.000 claims abstract 4
- 239000011630 iodine Substances 0.000 claims abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 210000003169 central nervous system Anatomy 0.000 claims 7
- 239000001961 anticonvulsive agent Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 230000007213 cerebrovascular event Effects 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000032109 Transient ischaemic attack Diseases 0.000 claims 3
- 208000006170 carotid stenosis Diseases 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000005809 status epilepticus Diseases 0.000 claims 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 3
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 208000028361 Penetrating Head injury Diseases 0.000 claims 2
- 229960003965 antiepileptics Drugs 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000021657 Birth injury Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108090000312 Calcium Channels Proteins 0.000 claims 1
- 102000003922 Calcium Channels Human genes 0.000 claims 1
- 208000014912 Central Nervous System Infections Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 108010062745 Chloride Channels Proteins 0.000 claims 1
- 102000011045 Chloride Channels Human genes 0.000 claims 1
- 208000018652 Closed Head injury Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000005189 Embolism Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000002091 Febrile Seizures Diseases 0.000 claims 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 206010063629 Hippocampal sclerosis Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- 206010028923 Neonatal asphyxia Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 108010052164 Sodium Channels Proteins 0.000 claims 1
- 102000018674 Sodium Channels Human genes 0.000 claims 1
- 208000002667 Subdural Hematoma Diseases 0.000 claims 1
- JACAAXNEHGBPOQ-LLVKDONJSA-N Talampanel Chemical compound C([C@H](N(N=1)C(C)=O)C)C2=CC=3OCOC=3C=C2C=1C1=CC=C(N)C=C1 JACAAXNEHGBPOQ-LLVKDONJSA-N 0.000 claims 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 150000001557 benzodiazepines Chemical class 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims 1
- 229960000623 carbamazepine Drugs 0.000 claims 1
- 238000013172 carotid endarterectomy Methods 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 238000002585 cerebral angiography Methods 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001076 chlorpromazine Drugs 0.000 claims 1
- 230000001886 ciliary effect Effects 0.000 claims 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims 1
- 229960001403 clobazam Drugs 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims 1
- 229960002767 ethosuximide Drugs 0.000 claims 1
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 claims 1
- 229960003472 felbamate Drugs 0.000 claims 1
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000035987 intoxication Effects 0.000 claims 1
- 231100000566 intoxication Toxicity 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 229960001848 lamotrigine Drugs 0.000 claims 1
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims 1
- 229960004002 levetiracetam Drugs 0.000 claims 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229940008015 lithium carbonate Drugs 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 238000002595 magnetic resonance imaging Methods 0.000 claims 1
- 229960001252 methamphetamine Drugs 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000003076 neurotropic agent Substances 0.000 claims 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 claims 1
- 229960001816 oxcarbazepine Drugs 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 229960002695 phenobarbital Drugs 0.000 claims 1
- 229960002036 phenytoin Drugs 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims 1
- 229960002393 primidone Drugs 0.000 claims 1
- 229960003312 retigabine Drugs 0.000 claims 1
- 230000004799 sedative–hypnotic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 229950004608 talampanel Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims 1
- 229960001918 tiagabine Drugs 0.000 claims 1
- 229960004394 topiramate Drugs 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 231100000167 toxic agent Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003440 toxic substance Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 229940102566 valproate Drugs 0.000 claims 1
- 238000007631 vascular surgery Methods 0.000 claims 1
- 229960005318 vigabatrin Drugs 0.000 claims 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims 1
- 230000004572 zinc-binding Effects 0.000 claims 1
- 229960002911 zonisamide Drugs 0.000 claims 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Spoj ili njegova farmaceutski prihvatljiva sol ili ester, naznačen time, da je izabran iz skupine koju čine Formula (I) i Formula (II): gdjefenil je supstituiran na X s jednim do pet atoma halogena izabranih iz skupine koju čine fluor, klor, brom i jod; teR1, R2, R3, R4, R5 i R6 su neovisno izabrani iz skupine koju čine vodik i C1-C4 alkil; gdje C1-C4 alkil je po izboru supstituiran s fenil (gdje fenil je po izboru supstituiran supstituentima neovisno izabranim iz skupine koju čine halogen, C1-C4 alkil, C1-C4 alkoksi, amino, nitro i cijano) za uporabu u liječenju prevencijom, reverzijom, zaustavljanjem ili sprečavanjem epileptogeneze kod ljudi kod kojih postoji rizik razvoja epilepsije ili poremećaja sa sličnim napadom, ali koji nema epilepsiju ili kliničku evidenciju napada. Patent sadrži još 39 patentnih zahtjeva.
Claims (40)
1. Spoj ili njegova farmaceutski prihvatljiva sol ili ester, naznačen time, da je izabran iz skupine koju čine Formula (I) i Formula (II):
[image]
gdje
fenil je supstituiran na X s jednim do pet atoma halogena izabranih iz skupine koju čine fluor, klor, brom i jod; te
R1, R2, R3, R4, R5 i R6 su neovisno izabrani iz skupine koju čine vodik i C1-C4 alkil; gdje C1-C4 alkil je po izboru supstituiran s fenil (gdje fenil je po izboru supstituiran supstituentima neovisno izabranim iz skupine koju čine halogen, C1-C4 alkil, C1-C4 alkoksi, amino, nitro i cijano) za uporabu u liječenju prevencijom, reverzijom, zaustavljanjem ili sprečavanjem epileptogeneze kod ljudi kod kojih postoji rizik razvoja epilepsije ili poremećaja sa sličnim napadom, ali koji nema epilepsiju ili kliničku evidenciju napada.
2. Spoj u skladu sa zahtjevom 1, naznačen time, da X je klor.
3. Spoj u skladu sa zahtjevom 1, naznačen time, da X je supstituiran u orto položaju fenilnog prstena.
4. Spoj u skladu sa zahtjevom 1, naznačen time, da R1, R2, R3, R4, R5 i R6 su izabrani kao vodik.
5. Enantiomer ili njegova farmaceutski prihvatljiva sol ili ester, naznačen time, da je izabran iz skupine koju čine Formula (I) i Formula (II) ili enantiomerna smjesa u kojoj prevladava jedan enantiomer izabran iz skupine koju čine Formula (I) i Formula (II):
[image]
gdje
fenil je supstituiran na X s jednim do pet atoma halogena izabranih iz skupine koju čine fluor, klor, brom i jod; te
R1, R2, R3, R4, R5 i R6 su neovisno izabrani iz skupine koju čine vodik i C1-C4 alkil; gdje C1-C4 alkil je po izboru supstituiran s fenil (gdje fenil je po izboru supstituiran supstituendima neovisno izabranim iz skupine koju čine halogen, C1-C4 alkil, C1-C4 alkoksi, amino, nitro i cijano) za uporabu u liječenju prevencijom, reverzijom, zaustavljanjem ili sprečavanjem epileptogeneze kod ljudi kod kojih postoji rizik razvoja epilepsije ili poremećaja sa sličnim napadom, ali koji nema epilepsiju ili kliničku evidenciju napada.
6. Enantiomer u skladu sa zahtjevom 5, naznačen time, da X je klor.
7. Enantiomer u skladu sa zahtjevom 5, naznačen time, da X je supstituiran u orto položaju fenilnog prstena.
8. Enantiomer u skladu sa zahtjevom 5, naznačen time, da R1, R2, R3, R4, R5 i R6 su izabrani kao vodik.
9. Enantiomer u skladu sa zahtjevom 5, naznačen time, da jedan enantiomer izabran iz skupine koju čine Formula (I) i Formula (II) prevladava do iznosa od oko 90% ili više.
10. Enantiomer u skladu sa zahtjevom 5, naznačen time, da jedan enantiomer izabran iz skupine koju čine Formula (I) i Formula (II) prevladava do iznosa od oko 98% ili više.
11. Enantiomer u skladu sa zahtjevom 5, naznačen time, da enantiomer izabran iz skupine koju čine Formula (I) i Formula (II) je enantiomer izabran iz skupine koju čine Formula (Ia) i Formula (IIa):
[image]
gdje
fenil je supstituiran na X s jednim do pet atoma halogena izabranih iz skupine koju čine fluor, klor, brom i jod; te
R1, R2, R3, R4, R5 i R6 su neovisno izabrani iz skupine koju čine vodik i C1-C4 alkil; gdje C1-C4 alkil je po izboru supstituiran s fenil (gdje fenil je po izboru supstituiran supstituendima neovisno izabranim iz skupine koju čine halogen, C1-C4 alkil, C1-C4 alkoksi, amino, nitro i cijano).
12. Enantiomer u skladu sa zahtjevom 11, naznačen time, da X je klor.
13. Enantiomer u skladu sa zahtjevom 11, naznačen time, da X je supstituiran u orto položaju fenilnog prstena.
14. Enantiomer u skladu sa zahtjevom 11, naznačen time, da R1, R2, R3, R4, R5 i R6 su izabrani kao vodik.
15. Enantiomer u skladu sa zahtjevom 11, naznačen time, da jedan enantiomer izabran iz skupine koju čine Formula (Ia) i Formula (IIa) prevladava do iznosa od oko 90% ili više.
16. Enantiomer u skladu sa zahtjevom 11, naznačen time, da jedan enantiomer izabran iz skupine koju čine Formula (Ia) i Formula (IIa) prevladava do iznosa od oko 98% ili više.
17. Enantiomer u skladu sa zahtjevom 5, naznačen time, da enantiomer izabran iz skupine koju čine Formula (I) i Formula (II) je enantiomer izabran iz skupine koju čine Formula (Ib) i Formula (IIb) ili njegova farmaceutski prihvatljiva sol ili ester:
[image]
18. Enantiomer u skladu sa zahtjevom 17, naznačen time, da jedan enantiomer izabran iz skupine koju čine Formula (Ib) i Formula (IIb) prevladava do iznosa od oko 90% ili više.
19. Enantiomer u skladu sa zahtjevom 17, naznačen time, da jedan enantiomer izabran iz skupine koju čine Formula (Ib) i Formula (IIb) prevladava do iznosa od oko 98% ili više.
20. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da predodređujući faktor (faktori) koji čini pacijenta rizičnim za razvoj epilepsije ili poremećaja sa sličnim napadom je izabran iz skupine koju čine: ozljeda ili trauma CNS-a bilo koje vrste; neurokirurški postupci; aktivnosti koje su rizične za oštećenje CNS-a, na primjer borbena djelovanja, auto trke ili konjske trke te kontaktni borilački sportovi uključujući i boks; oštećenje leđne moždine; infekcije CNS-a; anoksija; udar (CVAs); doživljeni prolazni ishemijski udar (TIAs); stenoza karotida; doživljeno aterosklerotično oboljenje krvnih žila; doživljena plućna embolija; oboljenje perifernih krvnih žila; autoimune bolesti koje djeluju na CNS, na primjer, lupus,ozljede prilikom rođenja poput perinatalne asfikcije; srčani arest; terapeutski ili dijagnostički postupci kirurgije krvnih žila, na primjer, karotidna endarterektomija ili cerebralna angiografija; hipotenzija; oštećenje CNS-a od embolije, hiper ili hipo perfuzije; hipoksija; poznata genetska predodređenost poremećajima poznatima da odgovaraju AEGDs; lezije CNS-a; tumori na mozgu, na primjer glioblastomi; krvarenja ili hemoragije u ili oko CNS-a, na primjer intracerebralna krvarenja ili subduralni hematomi; edem mozga; febrilne konvulzije; hipertermija; izloženost toksičnim ili otrovnim sredstvima; intoksikacija ili zlouporaba droga, na primjer kokaina, metamfetamina ili alkohola; obiteljska anamneza poremećaja s napadima ili neuroloških poremećaja s napadima sličnim epilepsiji, doživljeni status epilepticus; tijek liječenja lijekovima koji snižavaju prag napada, na primjer, litij karbonat, torazin ili klozapin; tragovi surogat markera ili biomarkera koje pacijent treba tijekom liječenja antiepilepticima, na primjer MRI scan koji pokazuje hipokampalnu sklerozu, povišeni serumski nivoi neuronskih razgradnih produkata, povišeni nivoi cilijarnog neuro-tropnog faktora (CNTF) ili EEG sugestivan za poremećaj s napadom ili neurološki poremećaj s napadom sličnim epilepsiji.
21. Spoj ili enantiomer u skladu sa zahtjevom 20, naznačen time, da predodređujući faktor (faktori) koji čini pacijenta rizičnim za razvoj epilepsije ili poremećaja sa sličnim napadom je izabran iz skupine koju čine: otvorena ili penetrirajuća trauma glave; neurokirurški postupci; karotidna stenoza, udar ili ostala cerebro-vaskularna događanja (CVA); status epilepticus i prostorne lezije CNS-a.
22. Spoj ili enantiomer u skladu sa zahtjevom 21, naznačen time, da navedeni predodređujući faktor (faktori) je zatvorena trauma glave ili penetrirajuća trauma glave ili neurokirurški postupak.
23. Spoj ili enantiomer u skladu sa zahtjevom 21, naznačen time, da navedeni predodređujući faktor (faktori) je udar, ostala cerebro-vaskularna događanja (CVA), prisutnost karotidne stenoze ili prolazni ishemijski događaj (TIAs).
24. Spoj ili enantiomer u skladu sa zahtjevom 23, naznačen time, da navedeni predodređujući faktor je status epilepticus.
25. Spojevi ili enantiomeri u skladu sa zahtjevom 1 ili 5, naznačeni time, da navedeni spoj (ili enantiomer) ili njegova farmaceutski prihvatljiva sol ili ester se primjenjuje u kombiniranoj primjeni s jednim ili više drugih spojeva ili terapeutskih sredstava.
26. Spojevi ili enantiomeri u skladu sa zahtjevom 25, naznačeni time, da jedan ili više drugih spojeva ili terapeutskih sredstava je izabran iz skupine koju čine spojevi koji imaju jedno ili više slijedećih svojstava: antioksadidativno djelovanje; antagonizam NMDA receptora; sposobnost da povećaju endogenu inhibiciju GABA; inhibicijsko djelovanje NO sintetaze; sposobnost vezivanja željeza, na primjer kelator željeza; sposobnost vezivanja kalcija, na primjer kelator Ca (II); sposobnost vezivanja cinka, na primjer kelator Zn (II); sposobnost blokiranja ionskih kanala natrija ili kalcija; sposobnost otvaranja ionskih kanala kalija ili klorida; terapeutska sredstva korisna u liječenju zlouporabe supstancija.
27. Spojevi ili enantiomeri u skladu sa zahtjevom 25, naznačeni time, da jedan ili više navedenih spojeva je izabran iz skupine koju čine anti-epileptički lijekovi (AEDs).
28. Spojevi ili enantiomeri u skladu sa zahtjevom 27, naznačeni time, da navedeni anti-epileptički lijek (AED) je izabran iz skupine koju čine: karbamazepin, klobazam, klonazepam, etosukcimid, felbamat, gabapentin, lamotigin, levetiracetam, okskarbazepin, fenobarbital, fenitoin, pregabalin, primidon, retigabin, talampanel, tiagabin, topiramat, valproat, vigabatrin, zonisamid, benzodiazepini, barbiturati ili sedativni hipnotici.
29. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da terapeutski učinkovita količina je od oko 5,7 mg/kg/dan do oko 42,9 mg/kg/dan.
30. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da se navedena terapeutski učinkovita količina postupno smanjuje kako napreduje postupak liječenja epileptogeneze kod navedenog pacijenta.
31. Spoj ili enantiomer u skladu sa zahtjevom 25, 26, 27 ili 28, naznačen time, da se količina navedenog jednog ili više drugih spojeva ili terapeutskih sredstava primjenjenih u kombinaciji s navedenim spojem (ili enantiomerom) ili njegove farmaceutski prihvatljive soli ili estera postupno smanjuje kako napreduje postupak liječenja epileptogeneze kod navedenog pacijenta.
32. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 6,4 mg/kg/dan do oko 35,7 mg/kg/dan.
33. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 7,1 mg/kg/dan do oko 28,6 mg/kg/dan.
34. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 7,9 mg/kg/dan do oko 21,4 mg/kg/dan.
35. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 8,6 mg/kg/dan do oko 17,1 mg/kg/dan.
36. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 400 mg/dan do oko 3000 mg/dan.
37. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 450 mg/dan do oko 2500 mg/dan.
38. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 500 mg/dan do oko 2000 mg/dan.
39. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 550 mg/dan do oko 1500 mg/dan.
40. Spoj ili enantiomer u skladu sa zahtjevom 1 ili 5, naznačen time, da primjenjena doza je od oko 600 mg/dan do oko 1200 mg/dan.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61027604P | 2004-09-16 | 2004-09-16 | |
| US69862505P | 2005-07-12 | 2005-07-12 | |
| US70724205P | 2005-08-11 | 2005-08-11 | |
| PCT/US2005/032861 WO2006033947A2 (en) | 2004-09-16 | 2005-09-15 | Use of 2-phenyl-1, 2-ethanediol- (di) carbamates for treating epileptogenesis and epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100304T1 true HRP20100304T1 (hr) | 2010-09-30 |
Family
ID=36087909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100304T HRP20100304T1 (hr) | 2004-09-16 | 2010-05-27 | Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20060194873A1 (hr) |
| JP (1) | JP2008513466A (hr) |
| KR (1) | KR20070057939A (hr) |
| CN (1) | CN101056629B (hr) |
| AT (1) | ATE464044T1 (hr) |
| AU (1) | AU2005287174B2 (hr) |
| BR (1) | BRPI0515374A (hr) |
| CA (1) | CA2580640A1 (hr) |
| CO (1) | CO6382111A2 (hr) |
| CR (1) | CR9053A (hr) |
| DE (1) | DE602005020667D1 (hr) |
| DK (1) | DK1809273T3 (hr) |
| EA (1) | EA200700642A1 (hr) |
| ES (1) | ES2342185T3 (hr) |
| HK (1) | HK1105583A1 (hr) |
| HR (1) | HRP20100304T1 (hr) |
| IL (1) | IL181910A0 (hr) |
| MX (1) | MX2007003278A (hr) |
| NO (1) | NO20071921L (hr) |
| NZ (1) | NZ553813A (hr) |
| PT (1) | PT1809273E (hr) |
| RS (1) | RS51269B (hr) |
| WO (1) | WO2006033947A2 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ517407A (en) * | 1999-08-10 | 2003-10-31 | Uab Research Foundation | Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy |
| CA2584854A1 (en) * | 2004-10-15 | 2006-04-27 | Janssen Pharmaceutica N.V. | Carbamate compounds for use in treating neurodegenerative disorders |
| PE20070325A1 (es) * | 2005-06-29 | 2007-05-12 | Alza Corp | Formas de dosificacion oral que comprenden compuestos derivados de carbamato |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| US20070043120A1 (en) * | 2005-08-18 | 2007-02-22 | Bettina Beyreuther | Therapeutic combination for painful medical conditions |
| TWI397417B (zh) | 2006-06-15 | 2013-06-01 | Ucb Pharma Gmbh | 具有協同抗驚厥功效之醫藥組成物 |
| WO2008045391A2 (en) * | 2006-10-06 | 2008-04-17 | Janssen Pharmaceutica Nv | Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| CA2667909A1 (en) * | 2006-10-31 | 2008-05-08 | Janssen Pharmaceutica N.V. | Treatment of pervasive developmental disorders |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| WO2013100566A1 (en) * | 2011-12-27 | 2013-07-04 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same |
| JP6062077B2 (ja) * | 2013-03-12 | 2017-01-18 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝ |
| JP6200527B2 (ja) * | 2013-03-12 | 2017-09-20 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 神経保護用フェニルカルバメート化合物及びこれを含む組成物 |
| JP6807941B2 (ja) * | 2016-02-29 | 2021-01-06 | バイオ−ファーム ソリューションズ カンパニー リミテッド | スルファメート誘導体化合物、その製造方法および用途 |
| CN106053510A (zh) * | 2016-05-16 | 2016-10-26 | 山东省分析测试中心 | 一种基于氢核磁共振快速测定普瑞巴林原料药纯度的方法 |
| KR102421006B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 두통의 예방학적 치료를 위한 카바메이트 화합물의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| AU3304997A (en) * | 1996-05-31 | 1998-01-05 | Southern Illinois University | Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation |
| DE60003791T2 (de) * | 1999-02-09 | 2004-02-05 | The University Of Virginia Alumni Patents Foundation | Felbamat-derivate |
| ES2304969T3 (es) * | 1999-07-26 | 2008-11-01 | Sk Holdings Co., Ltd. | Composiciones anticonvulsivas transnasales. |
| US6562867B2 (en) * | 2001-02-27 | 2003-05-13 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating bipolar disorder |
| NZ527989A (en) * | 2001-02-27 | 2005-12-23 | Ortho Mcneil Pharm Inc | Use of a halogenated 2-phenyl-1,2-ethanediol dicarbamate enantiomer or enantiomeric mixture wherein one enantiomer predominates for preventing or treating bipolar disorder |
| DE60220043T2 (de) * | 2001-02-27 | 2008-01-10 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen |
-
2005
- 2005-09-15 WO PCT/US2005/032861 patent/WO2006033947A2/en active Application Filing
- 2005-09-15 PT PT05810288T patent/PT1809273E/pt unknown
- 2005-09-15 MX MX2007003278A patent/MX2007003278A/es active IP Right Grant
- 2005-09-15 DK DK05810288.0T patent/DK1809273T3/da active
- 2005-09-15 CN CN2005800387418A patent/CN101056629B/zh active Active
- 2005-09-15 CA CA002580640A patent/CA2580640A1/en not_active Abandoned
- 2005-09-15 RS RSP-2010/0264A patent/RS51269B/sr unknown
- 2005-09-15 DE DE602005020667T patent/DE602005020667D1/de active Active
- 2005-09-15 ES ES05810288T patent/ES2342185T3/es active Active
- 2005-09-15 AU AU2005287174A patent/AU2005287174B2/en not_active Expired - Fee Related
- 2005-09-15 NZ NZ553813A patent/NZ553813A/en not_active IP Right Cessation
- 2005-09-15 KR KR1020077008402A patent/KR20070057939A/ko not_active Application Discontinuation
- 2005-09-15 AT AT05810288T patent/ATE464044T1/de active
- 2005-09-15 JP JP2007532446A patent/JP2008513466A/ja active Pending
- 2005-09-15 EA EA200700642A patent/EA200700642A1/ru unknown
- 2005-09-15 BR BRPI0515374-3A patent/BRPI0515374A/pt not_active IP Right Cessation
- 2005-09-15 US US11/227,247 patent/US20060194873A1/en not_active Abandoned
-
2007
- 2007-03-13 IL IL181910A patent/IL181910A0/en unknown
- 2007-03-29 CO CO07031825A patent/CO6382111A2/es not_active Application Discontinuation
- 2007-04-13 CR CR9053A patent/CR9053A/es not_active Application Discontinuation
- 2007-04-16 NO NO20071921A patent/NO20071921L/no not_active Application Discontinuation
- 2007-10-08 HK HK07110872.5A patent/HK1105583A1/xx unknown
- 2007-11-15 US US11/940,710 patent/US20110152362A1/en not_active Abandoned
-
2010
- 2010-05-27 HR HR20100304T patent/HRP20100304T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008513466A (ja) | 2008-05-01 |
| WO2006033947A3 (en) | 2006-06-29 |
| ES2342185T3 (es) | 2010-07-02 |
| CN101056629A (zh) | 2007-10-17 |
| DE602005020667D1 (de) | 2010-05-27 |
| PT1809273E (pt) | 2010-05-10 |
| RS51269B (sr) | 2010-12-31 |
| BRPI0515374A (pt) | 2008-07-22 |
| CO6382111A2 (es) | 2012-02-15 |
| AU2005287174B2 (en) | 2012-01-12 |
| NZ553813A (en) | 2010-09-30 |
| US20060194873A1 (en) | 2006-08-31 |
| AU2005287174A1 (en) | 2006-03-30 |
| EA200700642A1 (ru) | 2007-10-26 |
| IL181910A0 (en) | 2007-07-04 |
| US20110152362A1 (en) | 2011-06-23 |
| CN101056629B (zh) | 2012-01-11 |
| CA2580640A1 (en) | 2006-03-30 |
| ATE464044T1 (de) | 2010-04-15 |
| HK1105583A1 (en) | 2008-02-22 |
| NO20071921L (no) | 2007-06-12 |
| CR9053A (es) | 2009-10-30 |
| MX2007003278A (es) | 2007-10-08 |
| WO2006033947A2 (en) | 2006-03-30 |
| DK1809273T3 (da) | 2010-08-02 |
| KR20070057939A (ko) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100304T1 (hr) | Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze | |
| JP2009501224A5 (hr) | ||
| JP2009501223A5 (hr) | ||
| Masetti et al. | PRES in children undergoing hematopoietic stem cell or solid organ transplantation | |
| Barnett et al. | Granulocytic sarcoma of the brain: a case report and review of the literature. | |
| JP2004523555A5 (hr) | ||
| Miele et al. | Participation in contact or collision sports in athletes with epilepsy, genetic risk factors, structural brain lesions, or history of craniotomy | |
| JP2016537322A (ja) | Ｔｒｐａ１アンタゴニスト及び鎮痛剤を含む医薬組成物 | |
| Beaufrère et al. | Diagnosis of presumed acute ischemic stroke and associated seizure management in a Congo African grey parrot | |
| US20070021501A1 (en) | Methods of treating epileptogenesis | |
| Mortazavi et al. | Pediatric traumatic carotid, vertebral and cerebral artery dissections: a review | |
| US20070191460A1 (en) | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis | |
| Capo et al. | Efficacy and complications of radiotherapy of anterior visual pathway tumors | |
| CA2816911A1 (en) | Novel treatment of multiple sclerosis (ms) | |
| Drappatz et al. | Neurologic complications of plasma cell disorders | |
| Shah et al. | Neurological deficits among beta-thalassemia patients and its possible therapeutic intervention: a comprehensive review | |
| Wallach et al. | Protean neurologic manifestations of two rare dermatologic disorders: sweet disease and localized craniofacial scleroderma | |
| Gupta | Acute fatal stroke associated with honeybee sting | |
| URMAN et al. | Intracranial extramedullary hematopoiesis CT and bone marrow scan findings | |
| Chun | Dual phase 18F-FP CIT PET and 99mTc-ECD SPECT findings of Huntington's disease | |
| JP2022548631A (ja) | Ｋｖ７チャネル活性化剤の使用方法 | |
| Ritzenthaler et al. | Not everything that shakes is a seizure… Role of continuous EEG in the intensive care unit | |
| Sánchez-Larsen et al. | Cerebral vasospasm and wernicke encephalopathy secondary to adult cyclic vomiting syndrome: the role of magnesium | |
| Glantz et al. | The epidemiology and management of seizures in patients with cancer | |
| Galassi et al. | Amiodarone neurotoxicity: the other side of the medal |